Evidence map›Paper›PMID 34050415›Full record

ArticleBulletin of experimental biology and medicine2021

Drug Resistance of Mouse Somatic Cells to Rifampicin in Experimental Tuberculosis.

B V Nikonenko, I V Bocharova, L N Lepekha

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

B V NikonenkoCentral Research Institute for Tuberculosis, Moscow, Russia. boris.nikonenko52@gmail.com.
I V BocharovaCentral Research Institute for Tuberculosis, Moscow, Russia.
L N LepekhaCentral Research Institute for Tuberculosis, Moscow, Russia.
Central Scientific Research Institute of Tuberculosis Russian Academy of Medical Sciences · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have demonstrated that long-term exposure of intact mice to rifampicin (6 months) induces resistance to this drug, which manifested in inability of rifampicin to suppress the growth of Mycobacterium tuberculosis in the lungs and spleen during subsequent infection. It the same time, isoniazid is still effective in these mice. In this case, the phenomenon of somatic resistance to rifampicin in mice was observed if the treatment was started in a short period (within 4 days) after infection with M. tuberculosis. If the interval between infection and rifampicin administration was longer (3 weeks), the resistance disappeared.

Indexed as

Mycobacterium tuberculosisTuberculosisAnimalsAntitubercular AgentsDrug ResistanceIsoniazidMiceRifampinAntitubercular AgentsIsoniazidRifampindrug resistance of somatic cellsinbred miceisoniazidrifampicintuberculous inflammation

Identifiers

PMID34050415
OpenAlexW3165307118

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.